GLOBUS MEDICAL INC
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Except as set forth below, during the quarter ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).
On August 31, 2026, Kyle R. Kline, Chief Financial Officer and Senior Vice President, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Kline’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i)November 30, 2027 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 25,493 shares of Class A Common pursuant to the terms of the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.